EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation

Zhaojun Qiu, No-Joon Song, Anqi Li, Deepika Singh, Chandra B Prasad, Chunhong Yan, David P Carbone, Qi-En Wang, Xiaoli Zhang, Zihai Li, Junran Zhang

Journal of Clinical Investigation · 16.02.2026 · 136 (4)

DOI: 10.1172/jci193354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 18.12.2025. Verfasst von Zhaojun Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Protein Phosphatase 2, Lung Neoplasms, Immune Checkpoint Inhibitors, Nucleotidyltransferases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PP2A B55α, a regulatory subunit of protein phosphatase 2 (PP2A), is underexpressed in greater than 40% of non–small cell lung cancer (NSCLC) cases due to loss of heterozygosity of PPP2R2A , the gene encoding this protein. Given that low PPP2R2A expression correlates with poor prognosis, treating PPP2R2A-deficient NSCLC represents an unmet medical need. Here, we show that PPP2R2A knockdown or its heterozygosity ( PPP2R2A +/– ) increases cytosolic DNA, leading to cGAS-STING-type I IFN pathway activation. PPP2R2A deficiency results in elevated expression of immune checkpoint protein PD-L1 via GSK-3β- and STING-dependent mechanisms. PPP2R2A +/– cancer cells have enhanced sensitivity to PD-L1 blockade in a mouse model of lung cancer due to modulation of the tumor immune microenvironment, resulting in increased NK cells and reduced infiltration and function of Tregs. Consequently, PD-L1 antibody treatment increases CD8 + T infiltration and activity, especially in tumors with PPP2R2A heterozygosity. Furthermore, systemic or Treg-specific IFNAR1 blockade reduces the efficacy of PD-L1 blockade in PPP2R2A +/– tumors. Patients with NSCLC with a low PPP2R2A/PD-L1 ratio respond better to immune checkpoint blockade (ICB). These findings underscore the therapeutic potential of ICB in treating PPP2R2A-deficient NSCLC and suggest that PPP2R2A deficiency could serve as a biomarker for guiding ICB-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Phosphatase 2Lung NeoplasmsImmune Checkpoint InhibitorsNucleotidyltransferasesB7-H1 AntigenMembrane ProteinsCarcinoma, Non-Small-Cell LungNeoplasm ProteinsAnimalsHumansMiceMice, KnockoutTumor MicroenvironmentCell Line, TumorFemaleSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Stichwörter der Autor:innen

Cancer immunotherapyCell biologyImmunology

Substanzen

Protein Phosphatase 2STING1 protein, humanImmune Checkpoint InhibitorsNucleotidyltransferasesB7-H1 AntigenMembrane ProteinscGAS protein, humanCD274 protein, humanPPP2R2A protein, humancGAS protein, mouse

Autor:innen und Institutionen

  • The Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, Ohio, USA.
  • College of Medicine, and.
  • The James Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA.
  • Georgia Cancer Center, Augusta University Medical College, Augusta, Georgia, USA.
  • James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
  • USF Health, University of South Florida, Tampa, Florida, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Cancer Center
  • U.S. Department of Defense
  • nih

Zitieren

APA

Qiu, Z., Song, N. J., Li, A., Singh, D., Prasad, C. B., Yan, C., Carbone, D. P., Wang, Q. E., Zhang, X., Li, Z., & Zhang, J. (2026). PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. Journal of Clinical Investigation, 136(4). https://doi.org/10.1172/jci193354

Vancouver

Qiu Z, Song NJ, Li A, Singh D, Prasad CB, Yan C, et al. PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. Journal of Clinical Investigation. 2026;136(4). doi:10.1172/jci193354

BibTeX
@article{Qiu2026,
  author = {Qiu, Zhaojun and Song, No-Joon and Li, Anqi and Singh, Deepika and Prasad, Chandra B and Yan, Chunhong and Carbone, David P and Wang, Qi-En and Zhang, Xiaoli and Li, Zihai and Zhang, Junran},
  title = {PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {4},
  doi = {10.1172/jci193354}
}
Kostenlos starten →